Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
The European Commission’s compulsory licensing proposals are sensible but do not go far enough
An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...
Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
The US NIH will share technology with WHO to fight the pandemic
The US National Institutes of Health today committed to sharing several technologies with a World Health Organization body tasked with increasing access to Covid-19...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The European Commission’s proposal on a new EU-wide compulsory licensing regime
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London
A recent international health emergency, the...
Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...
Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations
This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...